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Abstract
Background: Somatotropinoma, a pituitary adenoma characterised by excessive production of growth hormone
(GH), is extremely rare in childhood. A genetic defect is evident in some cases; known genetic changes include:
multiple endocrine neoplasia type 1 (MEN1); Carney complex; McCune-Albright syndrome; and, more recently
identified, aryl hydrocarbon receptor-interacting protein (AIP). We describe seven children with somatotropinoma
with a special focus on the differences between genetic and sporadic forms.
Methods: Seven children who presented in our regional network between 1992 and 2008 were included in this
retrospective analysis. First-type therapy was somatostatin (SMS) analogues or transsphenoidal surgery. Control was
defined as when insulin-like growth factor-1 (IGF-1) levels were within the normal range for the patient’s age at 6
months after therapy, associated with decreasing tumour volume.
Results: Patients were aged 5-17 years and the majority (n = 6) were male. Four patients had an identified genetic
mutation (McCune-Albright syndrome: n = 1; MEN1: n = 1; AIP: n = 2); the remaining three cases were sporadic.
Accelerated growth rate was reported as the first clinical sign in four patients. Five patients presented with
macroadenoma; invasion was noted in four of them (sporadic: n = 1; genetic: n = 3). Six patients were treated with
SMS analogues; normalisation of IGF-1 occurred in one patient who had a sporadic intrasellar macroadenoma.
Multiple types of therapy were necessary in all patients with an identified genetic mutation (4 types: n = 1; 3 types:
n = 2; 2 types: n = 1), whereas two of the three patients with sporadic somatotropinoma required only one type
of therapy.
Conclusions: This is the first series that analyzes the therapeutic response of somatotropinoma in paediatric
patients with identified genetic defects. We found that, in children, genetic somatotropinomas are more invasive
than sporadic somatotropinomas. Furthermore, SMS analogues appear to be less effective for treating genetic
somatotropinoma than sporadic somatotropinoma.
Background
Somatotropinoma is a pituitary adenoma characterised
by excessive production of growth hormone (GH) from
the pituitary gland [1]. In adulthood, somatotropinoma is
associated with severe symptoms, including organome-
galy and dysmorphia [2], and diagnosis is usually delayed
by six years after the initial presentation of symptoms [3].
Somatotropinoma is rare in childhood and adolescence,
and there is little literature on this topic. As in adults,
diagnosis in children is delayed, but clinical presentation
differs with accelerated growth being the first symptom
observed after dysmorphic features [1].
Genetic defects have been recently identified in some
somatotropinoma cases. These defects include multiple
neoplasia syndromes, including the multiple endocrine
neoplasia type 1 (MEN1) [4,5], the Carney complex [6]
and McCune-Albright syndrome [7]. Recently, mutations
in the aryl hydrocarbon receptor interacting protein gene
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lated pituitary adenoma (FIPA) [8,9]. Such mutations
account for 15% of FIPA kindreds and are associated
with somatotropinomas, prolactinomas, non-secreting
adenomas and rare cases of Cushing disease [10]. We
present data on all children developing a somatotropi-
noma before 18 years of age between 1992 and 2008 in
our regional network for the management of paediatric
patients with endocrine disorders. Four of the children
presented with a known genetic defect. The aim of this
work was to analyse the clinical, biological, radiological
and therapeutic aspects of these adenomas.
Methods
All children (n = 7) with a GH-secreting pituitary ade-
noma that was diagnosed before 18 years of age in three
hospitals in France [Lyon (n = 5), Saint-Etienne (n = 1)
and Grenoble (n = 1)] were included in this analysis. One
case was diagnosed in 1992 (when the patient was six
years of age), and the other six cases were diagnosed
between 2005 and 2008. We excluded patients with GH-
independent gigantism, such as Beckwith-Wiedemann
syndrome or Sotos syndrome, and patients with GH-
releasing hormone secreting tumours.
A diagnosis of excessive production of GH was estab-
lished by a high level of serum GH over 24 hours, not
suppressible to <1 μg/L, 180 minutes after a 75 g oral
glucose tolerance test, or a high insulin-like growth fac-
tor-1 (IGF-1) level for the patient’s age.
Magnetic resonance imaging (MRI) was performed in
six cases; images were analysed by the same radiologists.
Invasiveness on MRI was assessed using the Hardy-
Vezina classification [11]. Tumours were considered as
invasive when presenting with extrasellar expansion to
the cavernous or sphenoidal sinus. For the oldest case,
computed-tomography scanning was performed in 1992,
and monitoring was done by MRI from 2000 onwards.
Immunometric assay
Serum GH levels were measured by radioimmunometric
assay calibrated to the WHO 98/574 standard. Before
1995, the GH assay (for one patient) was performed using
a polyclonal antibody kit.
Serum IGF-1 levels were measured using the IGF-1
RIACT kit (CIS Bio International). Results were presented
as standard deviation (SD), adjusted for sex, age and pub-
ertal stage. Prolactin was measured by radioimmunometric
assay calibrated on 84/500 standard. Other hormones of
the pituitary axis were also studied.
Treatment protocol
Somatostatin (SMS) analogues or transsphenoidal sur-
gery were the first-type treatment, depending on each
patient’s clinical evolution and criteria. Patients received
long-acting octreotide (10-30 mg) or lanreotide (30-120
mg), managed by the patient’s clinician, according to
IGF-1 level and growth curve. Patients also received
cabergoline at a dose of 0.5 mg once to three times
weekly.
Control was defined as when IGF-1 was within the nor-
mal range for the patient’s age at six months after therapy,
associated with a decreasing tumour volume of more than
30%. SMS analogue resistance was defined in the present
study as an IGF-1 level of more than +2 SD at six months
when receiving the maximum dose of octreotide or
lanreotide.
Results
Baseline clinical characteristics for the seven patients are
presented in Table 1.
Four patients (patients 2, 3, 5 and 7) presented for a clin-
ical consultation because of accelerated growth. (the
growth curve for patient 5 is shown in Figure 1). The other
patients presented for monitoring of McCune-Albright
syndrome (patient 1), gynaecomastia (patient 4) or
acquired resistance to cabergoline (patient 6). Acromegaly
was diagnosed in patient 1, three months after the onset of
McCune-Albright syndrome, with macrocrania, a cardiac
anomaly, enlarged hands and feet and nocturnal snoring.
Patients 3 and 4 both presented with headaches and visual
disturbances. Patient 6 had been treated with dopamine
agonists for a macroprolactinoma since ten years of age
and GH excess was suspected because of an acquired resis-
tance to cabergoline, headaches and enlarged hands and
feet. Only patients 2, 3 and 4 presented with a family his-
tory of pituitary adenomas (the family history of patients 3
and 4 is shown in Figure 2). Genetic analysis was positive
for MEN1 in patient 2 (intron 3, c.765-6C-> T-splicing
site) and AIP in patients 3 and 4 (exon 5, c.718T-> C- mis-
sense mutation), diagnosed at age 6, 13 and 16 years of
age, respectively. Extensive genetic analysis (MEN1, AIP,
Carney) was negative in patients 5 and 7, who were diag-
nosed at five and nine years of age, respectively. MEN1 and
AIP analyses were negative in patient 6. MRI revealed an
invasive macroadenoma with suprasellar and lateral exten-
sion to the cavernous sinus in patients 2, 3, 4 and 6, a non-
invasive intrasellar macroadenoma in patient 5 and a
microadenoma in patient 7.
Therapeutic data for the seven patients are presented
in Table 2 (FU: Follow-Up; C: Controlled; NC: Not
Controlled).
Transsphenoidal surgery was the first-type therapy in
patient 2 (presenting with visual defects due to chias-
matic compression) and patient 7 (presenting with a
sporadic microadenoma). Patient 7 was cured but
patient 2, with MEN1 and an invasive macroadenoma,
remained uncontrolled despite multiple types of treat-
ment (Table 2). Overall, six patients were treated with
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Page 2 of 8SMS analogues; in 5 patients (1, 3, 4, 5 and 6), this com-
prised first-type therapy. As shown in Figure 3, normali-
sation of IGF-1 occurred in only one case of sporadic
intrasellar macroadenoma (patient 5). In this patient, an
impressive tumoural response was observed with nor-
malization of MRI after 33 months. In the other five
cases, four of them being ofg e n e t i cf o r m ,I G F - 1w a s
not normalized, requiring additional types of therapy (3
types: n = 1; 2 types: n = 2; 1 type: n = 1).
At the end of treatment, four patients had normal IGF-
1 levels for their age, sex and pubertal stage (Figure 3,
Table 2). Normalization of IGF-1 levels occurred in two
Table 1 Baseline clinical characteristics of patients with somatotropinoma
Patient Sex Date of diagnosis Age at diagnosis (years) Symptoms/reason for consultation Size at diagnosis (SD)
1 Male 10/1992 6.5 Monitoring of McCune-Albright syndrome Bone deformity, non-measurable size
2 Female 01/06/2007 6.5 Accelerated growth +4
3 Male 29/06/2005 13 Accelerated growth +2
4 Male 18/01/2006 16.5 Headaches, gynaecomastia +3
5 Male 16/03/2006 5.5 Accelerated growth +4
6 Male 2008 17 Acquired resistance to cabergoline +0,5
7 Male 07/2006 9 Accelerated growth +4
Figure 1 Growth curve of patient 5. At the time of diagnosis, magnetic resonance imaging (MRI) showed a non-invasive macroadenoma.
Control was obtained with first-line somatostatin analogues. There was a correlation between decelerated growth, insulin-like growth factor-1
levels and disappearance of the macroadenoma on MRI.
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and 7) who received only one type of therapy and two
out of the four patients with a genetic form who received
2-3 types of therapy. Disease control was not achieved in
patients 2 and 3 and 6. A decrease in growth was
observed when disease control was achieved (Figure 1).
Discussion
This series of paediatric patients is one of the largest ser-
ies of somatotropinomas in children and gives new infor-
mation on the therapeutic management of this disease.
Recent epidemiological data have shown that the overall
prevalence of pituitary adenomas was greater than pre-
viously estimated. It was measured at 94.4 and 77.6/
100,000 inhabitants in the and Belgium [12] and United
Kingdom [13] respectively, with somatotropinomas
representing 13% and 11% of pituitary adenomas [12,13].
However, epidemiological data remain scarce in children.
In accordance with our results, the literature reports a
higher prevalence of GH-secreting pituitary adenomas in
boys than in girls [14-19]. This may be particularly true
for genetic forms, and particularly in patients with AIP-
related pituitary adenomas. Daly et al. showed recently in
a series of 96 AIP patients that 63.5% of them were male
[10]. In contrast, in a series of 83 a priori sporadic soma-
totropinomas in adults and young patients, Tichomirowa
et al. [20] observed that only 44.5% were male. However,
an AIP mutation was identified in eleven cases (13.3%),
and eight of them were men.
The presentation of somatotropinoma in children dif-
fers according to whether the epiphyseal plate has fused
or not. In the former situation, symptoms are similar to
those seen in acromegalic adults [1]. In contrast, if soma-
totropinoma occurs prior to fusion of the epiphyseal
plate, accelerated growth ensues with large size and
extreme “gigantism” [1]. In our series, four patients had
accelerated growth, two of whom had genetic forms of
somatotropinoma. Daly et al. showed that in adult
patients with AIP-related pituitary adenoma, gigantism
was significantly more frequent than in controls (32% vs.
6.5%; p < 0.000001) [10]. In our series, whatever the age
at diagnosis, the majority of patients presented with
enlarged hands and feet.
Most pituitary adenomas in childhood are macroadeno-
mas, and locally invasive tumours are frequently observed
[15,21]; headaches and visual disturbances are, therefore,
common [15,21,22]. In our series, five of seven patients
presented with macroadenoma; of these patients, four had
invasive macroadenomas, and three of these four had a
genetic mutation (one MEN1, two AIP). This is consistent
with the literature in adult patients, which reports larger
tumours and a more aggressive presentation in patients
with MEN1 versus without MEN1 (85% vs. 42%; p <
0.001) [4]. Recently, Daly et al. showed that the maximum
tumour diameter was higher in patients with AIP-related
somatotropinoma adenoma (n = 75) than in age-matched
AIP-negative patients (n = 232) (22.5 [7.0-60] vs. 16.0 [3.0-
48] mm; p < 0.00026) [10].
Moreover, four studies reported a high proportion of
genetic forms in children and young subjects [20,23-25].
Three of them [23-25] included, as did our study, seven
cases of acromegaly in young subjects, with identification
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Figure 2 Family history of patients 3 and 4.
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Page 4 of 8Table 2 Therapeutic intervention and follow-up in patients with somatotropinoma
Patient Genetic
mutation
IGF1 (μg/L) and
MRI at diagnosis
First-type therapy Second-type therapy Third-type
therapy
Fourth-
type
therapy
Control
of
disease
Last IGF1
(μg/L) and
MRI
F-U
(Years)
1 MAS 406 (+3SD)
Hyperplasia 565
(+4SD)
Octreotide LAR 30 mg (monthly- 18 months) + Cabergoline 1 mg/week Pegvisomant
20 mg/day
C 333 (-1SD)
NA
7
2 MENI Invasive
Macroadenoma (36
× 27 × 28 mm) 1259
(+4SD)
Trans-sphenoidal surgery Octreotide LAR 30 mg monthly (6
months - growth of adenoma with
visual disturbance; 3 surgeries)
+ Cabergoline
with visual (1
mg/week)
Proton
therapy
NC 689 (+2.5SD)
14 × 10 mm
(-68%)
3
3 AIP Invasive
Macroadenoma (21
× 26 mm) 997
(+4SD)
Lanreotide LAR 90 mg monthly (6 months) Octreotide LAR 30 mg monthly +
cabergoline (1 mg/week)
Transphenoidal
surgery
NC 1184 (+4SD)
10 × 12 × 9
mm (-50%)
4
4 AIP Invasive
Macroadenoma (16
× 21 × 11 mm) 934
(+4SD)
Lanreotide LAR 60 mg monthly (6 months) Transphenoidal surgery C 451 (0SD) No
visible
adenoma
6
5 Negative
genetic analysis
(Carney, MEN1,
AIP)
Non invasive
macroadenoma (19
× 14 × 20 mm)
Lanreotide LAR 60 mg monthly C 282 (+1SD)
No visible
adenoma
4
6 Negative
genetic analysis
(MEN1, AIP)
777 (+3SD) Invasive
macroadenoma (26
× 26 × 32 mm)
Octreotide LAR 30 mg monthly (6 months)
added to the previous Dopamine agonist
treatment (Cabergoline 1,5 mg/week)
NC 717(+3SD) 34
×2 1×2 3
mm (+6%)
2
7 Negative
genetic analysis
(Carney, MEN1,
AIP)
574 (+4SD)
Microadenoma (7,6
× 9 × 7,5 mm)
Trans-sphenoidal surgery C 504 (+1,5 SD)
No visible
adenoma
4
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8of a genetic form in 2-4 cases. In the fourth study, con-
ducted by Tichomirowa et al., which included 39 patients
with a pituitary macroadenoma diagnosed before 18
years, an AIP mutation was identified in 20.5% of cases
[20].
In both adults and children, conventional treatment of
somatotropinoma is transsphenoidal surgery [15,18]. In
cases of intracavernous extension, or when surgery has
been incomplete, pre- and/or post-operative SMS analo-
gue treatment may be administered [16,26] and has been
shown to be safe in paediatric patients [14]. The GH
receptor antagonist pegvisomant, or cabergoline in cases
of somato-prolactinomas, can be used in acromegalic
patients who have failed to respond to conventional treat-
ment [14,27]. In our region, SMS analogues were effective
in one of the six cases in whom they were used.
Cabergoline was administered to two patients in our ser-
ies (both with genetic somatotropinoma) as second-type
therapy in combination with SMS analogues. One of these
patients required no further therapy, while the other (who
had McCune-Albright syndrome) was switched to pegvi-
somant, which successfully reduced IGF-1 levels to -1 SD,
consistent with the literature [28,29].
Inadults,geneticformsofsomatotropinomaaremoredif-
ficult to control than sporadic forms. In a study of adult
patients with pituitary adenomas, Verges et al. observed a
normalization ofpituitary hypersecretion in90% ofpatients
with sporadic adenomas and 42% of patients with MEN1
genetic alterations[4]. To date, little is known on the thera-
peutic response in children. Personnier et al., in a recent
review, observed that GH control was obtained in 69% of
cases in children [30]; in that analysis, genetic and sporadic
forms were analyzed together. Accordingly, in another ser-
ies of eleven sporadic paediatric pituitary adenomas, six
were considered to be controlled by SMS analogues before
andaftersurgery.Tumoursizewasreducedby51.0%overall
[14].In contrast, Tichomirowa et al. [20]observed that, in a
series of eleven paediatric and young patients with an AIP-
relatedsomatotropinoma,atleasttwosurgicalinterventions
were necessary in 36.4% of cases, and that post-operative
SMS analogue therapy was only effective in 11% of patients
[20]. In our series, control was achieved in two out of the
three patients with a sporadic somatotropinoma after one
type of therapy. In contrast, all patients with genetic soma-
totropinoma required two (n = 2) or three (n = 2) types of
therapy, and only two out of four such patients were cured.
ThreepatientsreceivedSMSanaloguesasfirst-typetherapy;
these were followed by cabergoline, pegvisomant or trans-
sphenoidal surgery. In the fourth patient, transsphenoidal
surgerywasineffectiveasfirst-typetherapy,andIGF-1levels
remained +2 SD even after subsequent SMS analogues and
radiotherapy. These findings suggest that SMS analogues
havelittleefficacyinpatientswithgeneticsomatotropinoma
and that,asreportedinadults[4], hormonalcontrolismore
difficult to achieve in patients with genetic somatotropino-
masthaninpatientswithsporadicforms.
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Figure 3 Change in insulin-like growth factor-1 levels during somatostatin (SMS) analogue therapy. Only patient 5, with intrasellar
macroadenoma and a sporadic form, was controlled after first-line SMS analogues.
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Somatotropinomas in children and adolescents are rare
and more aggressive than those seen in adults. In this
small series of patients, genetic somatotropinomas were
more invasive than sporadic somatotropinomas. Our data
suggest that SMS analogues, while effective in sporadic
somatotropinoma, are less effective in genetic somatotropi-
noma. Further research on the incidence and types of
genetic mutations in children and adolescents with soma-
totropinoma is necessary to increase our understanding of
the disease. In addition, studies of different therapeutic
options in genetic somatotropinoma would provide more
information about why SMS analogues are less effective in
these patients, and allow for the development of new treat-
ment strategies in this setting.
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